Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Oncology

Roche’s Columvi Phase III STARGLO Trial; ...

Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phas...

Apr 16, 2024

enhertu-for-her2-positive-solid-tumors
ENHERTU: Another Triumph to Celebrate for AstraZeneca and Daiichi Sankyo

ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...

Find More
doc1021-phase-i-results
DOC1021 – Unveiling Hope: Diakonos Oncology’s Breakthrough in Glioblastoma Treatment: AACR 2024

Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed. At AACR ...

Find More
phase-i-ii-trial-of-copanlisib
Phase I/II trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC)

The findings presented at the 2024 AACR conference revealed that among patients diagnosed with PIK3Ca-mutated MSS mCRC (n = 22), three patients attained a partial response (PR). Additionally, one more patient with PIK3Ca-mutated mCRC maintained stable disease (SD). The study successfully achieved its primary endpoi...

Find More

More Views & Analysis

obx-115-phase-i-trial-result
OBX-115 – TIL Cell Therapy Advancements for ICI-Resistant Advanced Melanoma: AACR 2024

Melanoma, a type of skin cancer, poses a significant health concern globally. Advanced and metastatic stages of melanoma present particularly formidable challenges, often necessitating innovative treatment approaches to address their aggressive nature and high mortality rates. Patients with ICI-resistant metasta...

Find More

tg4050-phase-i-trial
Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV-negative head and neck cancers

TG4050 is a neoantigenic cancer vaccine derived from Transgene's myvac platform and leverages NEC's Artificial Intelligence (AI) technologies to identify and predict the most potent neoantigens for immunogenicity. According to the data presented at the AACR 2024 conference, at a median follow-up duration of 18.6 mo...

Find More

alx-oncology-evorpacept-combo
ALX Oncology’s Evorpacept Combo Shows Strong Response in Relapsed B-NHL Patients: AACR 2024

The presentation by ALX Oncology at the AACR Annual Meeting 2024 provided promising insights into the efficacy and safety of their investigational drug, evorpacept, in combination with standard rituximab and lenalidomide for patients with relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). The Phase ...

Find More

azd1390-for-glioblastoma
Safety and preliminary efficacy of AZD1390 + radiation therapy (RT) for glioblastoma (GBM)

As per the data presented at the AACR 2024 conference, of the 21 patients who received AZD1390 in conjunction with radiation therapy at manageable doses, the median overall survival (OS) stood at 12.7 months. In arm A, comprising 75 patients with recurrent glioblastoma, the combination therapy of AZD1390 and IMR...

Find More

alectinib-promising-efficacy-and-tolerability
Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study

According to the data presented at the AACR 2024 conference, as of the data cutoff date of June 12, 2023, a total of 8 patients at a median age of 11 years diagnosed with inflammatory myofibroblastic tumor (n=2), high-grade glioma (n=3), renal cell carcinoma (n=2), and anaplastic large cell lymphoma (n=1, protocol ...

Find More

nbf-006-promising-results
First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer

Glutathione S‑transferase Pi (GSTP) has a role in detoxification and anti‑oxidative damage response. Additionally, GSTP has a chaperone function that regulates key oncogenic pathways such as the KRAS and JNK. Since redundant pathways could compensate for the inhibition of a single kinase, targeting multiple pathway...

Find More

T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....

Find More

A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning .....

Find More

A genetic disorder, Duchenne Muscular Dystrophy (DMD), is a progressive form of muscular dystrophy w.....

Find More

A rare neurological disorder characterized by progressive weakness and impaired sensory function in .....

Find More

Atrial fibrillation market is brimming with novel therapies in different stages of clinical developm.....

Find More

Retinitis pigmentosa is a gradual deterioration of the ability of eyes to see. The defect in the eye.....

Find More